Eric Joseph
Stock Analyst at JP Morgan
(2.02)
# 1,614
Out of 4,496 analysts
96
Total ratings
39.68%
Success rate
-8.28%
Average return
Main Sectors:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $34 | $20.78 | +63.62% | 6 | Jul 15, 2024 | |
| HLVX HilleVax | Downgrades: Neutral | n/a | $1.77 | - | 4 | Jul 8, 2024 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $53 | $32.63 | +62.43% | 5 | Jun 20, 2024 | |
| PRME Prime Medicine | Maintains: Overweight | $16 → $15 | $5.31 | +182.75% | 4 | May 13, 2024 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $12 | $10.03 | +19.64% | 4 | May 3, 2024 | |
| BMEA Biomea Fusion | Maintains: Neutral | n/a | $5.04 | - | 1 | May 3, 2024 | |
| TGTX TG Therapeutics | Reiterates: Overweight | $25 | $21.00 | +19.05% | 3 | Apr 18, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $55 → $50 | $22.82 | +119.11% | 1 | Feb 27, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $34 → $47 | $43.10 | +9.05% | 2 | Feb 23, 2024 | |
| ENTA Enanta Pharmaceuticals | Maintains: Underweight | $12 → $11 | $14.32 | -23.18% | 3 | Feb 8, 2024 | |
| CCCC C4 Therapeutics | Upgrades: Neutral | $6 | $6.03 | -0.50% | 4 | Jan 29, 2024 | |
| BEAM Beam Therapeutics | Upgrades: Overweight | $38 → $40 | $25.94 | +54.20% | 2 | Jan 29, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Neutral | $11 → $10 | $7.61 | +31.41% | 2 | Nov 13, 2023 | |
| RVMD Revolution Medicines | Maintains: Overweight | $47 → $39 | $46.14 | -15.47% | 3 | Nov 7, 2023 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $31 → $11 | $4.26 | +158.22% | 2 | Oct 19, 2023 | |
| AKRO Akero Therapeutics | Maintains: Overweight | $62 → $41 | $26.76 | +53.21% | 2 | Oct 11, 2023 | |
| LYEL Lyell Immunopharma | Downgrades: Neutral | $15 → $5 | $1.56 | +220.51% | 1 | Aug 28, 2023 | |
| IPSC Century Therapeutics | Downgrades: Neutral | $28 → $5 | $2.50 | +100.00% | 2 | Aug 28, 2023 | |
| PLRX Pliant Therapeutics | Maintains: Overweight | $47 → $48 | $12.36 | +288.35% | 3 | Aug 10, 2023 | |
| AVIR Atea Pharmaceuticals | Downgrades: Underweight | n/a | $3.57 | - | 5 | Aug 10, 2023 | |
| TERN Terns Pharmaceuticals | Maintains: Neutral | $10 → $11 | $8.49 | +29.64% | 6 | Aug 9, 2023 | |
| IGMS IGM Biosciences | Maintains: Neutral | $26 → $19 | $10.74 | +76.91% | 3 | May 16, 2023 | |
| BLUE bluebird bio | Initiates: Overweight | $7 | $1.05 | +566.67% | 1 | Apr 28, 2023 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $42 → $29 | $8.60 | +237.21% | 3 | Apr 19, 2023 | |
| SRZN Surrozen | Downgrades: Underweight | n/a | $9.00 | - | 2 | Nov 29, 2022 | |
| NVAX Novavax | Downgrades: Underweight | $132 → $27 | $13.85 | +94.95% | 5 | Sep 22, 2022 | |
| KPTI Karyopharm Therapeutics | Upgrades: Neutral | $8 | $0.89 | +798.88% | 2 | Feb 9, 2022 | |
| ALGS Aligos Therapeutics | Downgrades: Neutral | $30 → $12 | $0.50 | +2,282.37% | 1 | Jan 7, 2022 | |
| OMER Omeros | Downgrades: Underweight | n/a | $4.88 | - | 2 | Oct 8, 2021 | |
| VERV Verve Therapeutics | Initiates: Neutral | n/a | $6.89 | - | 1 | Jul 12, 2021 | |
| ACHL Achilles Therapeutics | Initiates: Underweight | n/a | $0.84 | - | 1 | Apr 26, 2021 | |
| AUTL Autolus Therapeutics | Downgrades: Neutral | n/a | $4.25 | - | 2 | Jan 29, 2021 | |
| AKBA Akebia Therapeutics | Downgrades: Underweight | n/a | $1.35 | - | 1 | Jan 29, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Overweight | n/a | $5.75 | - | 1 | Feb 24, 2020 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Neutral | n/a | $6.72 | - | 2 | Jan 24, 2019 | |
| SGMO Sangamo Therapeutics | Maintains: Neutral | n/a | $0.40 | - | 2 | Nov 14, 2018 | |
| OPK OPKO Health | Downgrades: Underweight | n/a | $1.49 | - | 2 | Mar 2, 2018 |
Nurix Therapeutics
Jul 15, 2024
Maintains: Overweight
Price Target: $31 → $34
Current: $20.78
Upside: +63.62%
HilleVax
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.77
Upside: -
PTC Therapeutics
Jun 20, 2024
Maintains: Overweight
Price Target: $53
Current: $32.63
Upside: +62.43%
Prime Medicine
May 13, 2024
Maintains: Overweight
Price Target: $16 → $15
Current: $5.31
Upside: +182.75%
Vir Biotechnology
May 3, 2024
Maintains: Neutral
Price Target: $10 → $12
Current: $10.03
Upside: +19.64%
Biomea Fusion
May 3, 2024
Maintains: Neutral
Price Target: n/a
Current: $5.04
Upside: -
TG Therapeutics
Apr 18, 2024
Reiterates: Overweight
Price Target: $25
Current: $21.00
Upside: +19.05%
Rocket Pharmaceuticals
Feb 27, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $22.82
Upside: +119.11%
Kymera Therapeutics
Feb 23, 2024
Maintains: Overweight
Price Target: $34 → $47
Current: $43.10
Upside: +9.05%
Enanta Pharmaceuticals
Feb 8, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $14.32
Upside: -23.18%
C4 Therapeutics
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $6.03
Upside: -0.50%
Beam Therapeutics
Jan 29, 2024
Upgrades: Overweight
Price Target: $38 → $40
Current: $25.94
Upside: +54.20%
Recursion Pharmaceuticals
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $7.61
Upside: +31.41%
Revolution Medicines
Nov 7, 2023
Maintains: Overweight
Price Target: $47 → $39
Current: $46.14
Upside: -15.47%
Monte Rosa Therapeutics
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.26
Upside: +158.22%
Akero Therapeutics
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $26.76
Upside: +53.21%
Lyell Immunopharma
Aug 28, 2023
Downgrades: Neutral
Price Target: $15 → $5
Current: $1.56
Upside: +220.51%
Century Therapeutics
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.50
Upside: +100.00%
Pliant Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $47 → $48
Current: $12.36
Upside: +288.35%
Atea Pharmaceuticals
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.57
Upside: -
Terns Pharmaceuticals
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.49
Upside: +29.64%
IGM Biosciences
May 16, 2023
Maintains: Neutral
Price Target: $26 → $19
Current: $10.74
Upside: +76.91%
bluebird bio
Apr 28, 2023
Initiates: Overweight
Price Target: $7
Current: $1.05
Upside: +566.67%
Relay Therapeutics
Apr 19, 2023
Maintains: Overweight
Price Target: $42 → $29
Current: $8.60
Upside: +237.21%
Surrozen
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $9.00
Upside: -
Novavax
Sep 22, 2022
Downgrades: Underweight
Price Target: $132 → $27
Current: $13.85
Upside: +94.95%
Karyopharm Therapeutics
Feb 9, 2022
Upgrades: Neutral
Price Target: $8
Current: $0.89
Upside: +798.88%
Aligos Therapeutics
Jan 7, 2022
Downgrades: Neutral
Price Target: $30 → $12
Current: $0.50
Upside: +2,282.37%
Omeros
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.88
Upside: -
Verve Therapeutics
Jul 12, 2021
Initiates: Neutral
Price Target: n/a
Current: $6.89
Upside: -
Achilles Therapeutics
Apr 26, 2021
Initiates: Underweight
Price Target: n/a
Current: $0.84
Upside: -
Autolus Therapeutics
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.25
Upside: -
Akebia Therapeutics
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.35
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Overweight
Price Target: n/a
Current: $5.75
Upside: -
Ironwood Pharmaceuticals
Jan 24, 2019
Upgrades: Neutral
Price Target: n/a
Current: $6.72
Upside: -
Sangamo Therapeutics
Nov 14, 2018
Maintains: Neutral
Price Target: n/a
Current: $0.40
Upside: -
OPKO Health
Mar 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $1.49
Upside: -